第 48 卷第 4 期 Vol. 48 No. 4 2018 年 8 月 Aug 2018

所属栏目：专论与综述 ALK抑制剂上市药物的研发历程

张溢凡 （中国人民解放军93575部队卫生队，河北 承德 067000）

摘　要：ALK为间变性淋巴瘤激酶，是胰岛素受体酪氨酸激酶家族中的一员。ALK基因在多种肿瘤细胞中异常活跃，是抗肿瘤药物研究中较为成熟的重要靶标之一。主要对ALK的结构与功能、EML4-ALK融合基因信号通路在治疗NSCLC中的调控作用以及目前已经上市的ALK抑制剂的研发历程进行综述，旨在为药物，特别是以ALK为靶点的药物研发提供指导。

关键词：ALK抑制剂；EML4-ALK融合基因；非小细胞肺癌（NSCLC）

中图分类号：R971　　文献标识码：B　　文章编号：1009-9212（2018）04-0008-08

Development History of Marketed ALK Inhibitors

ZHANG Yi-fan (Health Unit of 93575 Troop, the People's Liberation Army of China, Chengde 067000, China)

Abstract：ALK, an anaplastic lymphoma kinase, is a member of the insulin receptor tyrosine kinase family. It was observed that the ALK gene was extremely active in a variety of tumor cells and was an important target for the study of antitumor drugs. This review mainly discussed the structure and function of ALK, and the role of the EML4-ALK mutations signaling pathway in treating NSCLC. Meanwhile, the development process of currently marketed ALK inhibitors was also described focusing on providing effective research ideas for developing new drugs based on ALK or other targets.

Key words：ALK inhibitor; EML4-ALK mutations; non-small cell lung cancer (NSCLC)

作者简介：张溢凡（1991-），男，河南郑州人，药师，主要从事生物技术研究（E-mail：149889071@qq.com）。

收稿日期： 2018-06-2